CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will present an update on Company progress at two upcoming conferences in March using a virtual platform.

Read the original post:
TCR² Therapeutics to Participate in Two Upcoming Conferences in March

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *